IBDEI0TF ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13239,2)
 ;;=^5005907
 ;;^UTILITY(U,$J,358.3,13240,0)
 ;;=H40.61X2^^51^632^49
 ;;^UTILITY(U,$J,358.3,13240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13240,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Moderate Stage
 ;;^UTILITY(U,$J,358.3,13240,1,4,0)
 ;;=4^H40.61X2
 ;;^UTILITY(U,$J,358.3,13240,2)
 ;;=^5005908
 ;;^UTILITY(U,$J,358.3,13241,0)
 ;;=H40.61X3^^51^632^50
 ;;^UTILITY(U,$J,358.3,13241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13241,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Severe Stage
 ;;^UTILITY(U,$J,358.3,13241,1,4,0)
 ;;=4^H40.61X3
 ;;^UTILITY(U,$J,358.3,13241,2)
 ;;=^5133509
 ;;^UTILITY(U,$J,358.3,13242,0)
 ;;=H40.61X4^^51^632^51
 ;;^UTILITY(U,$J,358.3,13242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13242,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,13242,1,4,0)
 ;;=4^H40.61X4
 ;;^UTILITY(U,$J,358.3,13242,2)
 ;;=^5005909
 ;;^UTILITY(U,$J,358.3,13243,0)
 ;;=H40.813^^51^632^64
 ;;^UTILITY(U,$J,358.3,13243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13243,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
 ;;^UTILITY(U,$J,358.3,13243,1,4,0)
 ;;=4^H40.813
 ;;^UTILITY(U,$J,358.3,13243,2)
 ;;=^5005921
 ;;^UTILITY(U,$J,358.3,13244,0)
 ;;=H40.811^^51^632^62
 ;;^UTILITY(U,$J,358.3,13244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13244,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
 ;;^UTILITY(U,$J,358.3,13244,1,4,0)
 ;;=4^H40.811
 ;;^UTILITY(U,$J,358.3,13244,2)
 ;;=^5005919
 ;;^UTILITY(U,$J,358.3,13245,0)
 ;;=H40.812^^51^632^63
 ;;^UTILITY(U,$J,358.3,13245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13245,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
 ;;^UTILITY(U,$J,358.3,13245,1,4,0)
 ;;=4^H40.812
 ;;^UTILITY(U,$J,358.3,13245,2)
 ;;=^5005920
 ;;^UTILITY(U,$J,358.3,13246,0)
 ;;=H40.823^^51^632^67
 ;;^UTILITY(U,$J,358.3,13246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13246,1,3,0)
 ;;=3^Hypersecretion GLC,OU
 ;;^UTILITY(U,$J,358.3,13246,1,4,0)
 ;;=4^H40.823
 ;;^UTILITY(U,$J,358.3,13246,2)
 ;;=^5005925
 ;;^UTILITY(U,$J,358.3,13247,0)
 ;;=H40.821^^51^632^65
 ;;^UTILITY(U,$J,358.3,13247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13247,1,3,0)
 ;;=3^Hypersecretion GLC,OD
 ;;^UTILITY(U,$J,358.3,13247,1,4,0)
 ;;=4^H40.821
 ;;^UTILITY(U,$J,358.3,13247,2)
 ;;=^5005923
 ;;^UTILITY(U,$J,358.3,13248,0)
 ;;=H40.822^^51^632^66
 ;;^UTILITY(U,$J,358.3,13248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13248,1,3,0)
 ;;=3^Hypersecretion GLC,OS
 ;;^UTILITY(U,$J,358.3,13248,1,4,0)
 ;;=4^H40.822
 ;;^UTILITY(U,$J,358.3,13248,2)
 ;;=^5005924
 ;;^UTILITY(U,$J,358.3,13249,0)
 ;;=H40.43X0^^51^632^27
 ;;^UTILITY(U,$J,358.3,13249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13249,1,3,0)
 ;;=3^Inflam GLC,OU,Stage Unspec
 ;;^UTILITY(U,$J,358.3,13249,1,4,0)
 ;;=4^H40.43X0
 ;;^UTILITY(U,$J,358.3,13249,2)
 ;;=^5005878
 ;;^UTILITY(U,$J,358.3,13250,0)
 ;;=H40.43X1^^51^632^28
 ;;^UTILITY(U,$J,358.3,13250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13250,1,3,0)
 ;;=3^Inflam GLC,OU,Mild Stage
 ;;^UTILITY(U,$J,358.3,13250,1,4,0)
 ;;=4^H40.43X1
 ;;^UTILITY(U,$J,358.3,13250,2)
 ;;=^5005879
 ;;^UTILITY(U,$J,358.3,13251,0)
 ;;=H40.43X2^^51^632^29
 ;;^UTILITY(U,$J,358.3,13251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13251,1,3,0)
 ;;=3^Inflam GLC,OU,Moderate Stage
 ;;^UTILITY(U,$J,358.3,13251,1,4,0)
 ;;=4^H40.43X2
 ;;^UTILITY(U,$J,358.3,13251,2)
 ;;=^5005880
